# Anti-obesity Pharmacotherapy and Inflammation

> **NCT05756764** · — · ACTIVE_NOT_RECRUITING · sponsor: **Louisiana State University Health Sciences Center in New Orleans** · enrollment: 30 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Phentermine-Topiramate combination
- **DRUG:** Phentermine
- **DRUG:** Tirzepatide
- **DRUG:** Topiramate
- **DRUG:** Diethylpropion
- **DRUG:** Naltrexone/Bupropion
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT05756764
- **Lead sponsor:** Louisiana State University Health Sciences Center in New Orleans
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-02-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05756764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05756764, "Anti-obesity Pharmacotherapy and Inflammation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05756764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*